

Anti-COX2 PTGS2 Rabbit Monoclonal Antibody

Catalog # ABO13393

Product Information

Application	WB, IF, ICC
Primary Accession	P35354
Host	Rabbit
Isotype	Rabbit IgG
Reactivity	Human, Mouse
Clonality	Monoclonal
Format	Liquid
Description	Anti-COX2 PTGS2 Rabbit Monoclonal Antibody . Tested in WB, ICC/IF applications. This antibody reacts with Human, Mouse.

Additional Information

Gene ID	5743
Other Names	Prostaglandin G/H synthase 2, 1.14.99.1, Cyclooxygenase-2, COX-2, PHS II, Prostaglandin H2 synthase 2, PGH synthase 2, PGHS-2, Prostaglandin-endoperoxide synthase 2, PTGS2 (HGNC:9605)
Calculated MW	68996
Application Details	WB 1:500-1:1000 ICC/IF 1:50-1:200
Subcellular Localization	Microsome membrane; Peripheral membrane protein. Endoplasmic reticulum membrane; Peripheral membrane protein.
Source	Eukaryota
Contents	Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.
Clone Names	Clone: EEC-16
Immunogen	A synthesized peptide derived from human COX2
Purification	Affinity-chromatography
Storage	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.

Protein Information

Name	PTGS2 (HGNC:9605)
-------------	-------------------------------------


Function

Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response (PubMed:[11939906](#), PubMed:[16373578](#), PubMed:[19540099](#), PubMed:[22942274](#), PubMed:[26859324](#), PubMed:[27226593](#), PubMed:[7592599](#), PubMed:[7947975](#), PubMed:[9261177](#)). The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes (PubMed:[16373578](#), PubMed:[22942274](#), PubMed:[26859324](#), PubMed:[27226593](#), PubMed:[7592599](#), PubMed:[7947975](#), PubMed:[9261177](#)). This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S- stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons (PubMed:[16373578](#), PubMed:[22942274](#), PubMed:[26859324](#), PubMed:[27226593](#), PubMed:[7592599](#), PubMed:[7947975](#), PubMed:[9261177](#)). Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins (PubMed:[11939906](#), PubMed:[19540099](#)). In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophospholipids to prostanoid lysophospholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids (PubMed:[27642067](#)). Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response (PubMed:[22942274](#)). Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols (PubMed:[11034610](#), PubMed:[11192938](#), PubMed:[9048568](#), PubMed:[9261177](#)). Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation (PubMed:[12391014](#)). Metabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs) (PubMed:[12391014](#)). As a component of the biosynthetic pathway of E- series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2 (PubMed:[21206090](#)). In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R- HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection (PubMed:[26236990](#)). In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11- diHETE) (PubMed:[22068350](#), PubMed:[26282205](#)). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)- HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity). During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity).


Cellular Location

Microsome membrane; Peripheral membrane protein. Endoplasmic reticulum membrane; Peripheral membrane protein. Nucleus inner membrane; Peripheral membrane protein. Nucleus outer membrane; Peripheral membrane protein. Note=Detected on the luminal side of the endoplasmic reticulum and nuclear envelope


Images




All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.




Immunofluorescent analysis using the Antibody at 1:50 dilution.




Immunofluorescent analysis using the Antibody at 1:50 dilution.




Immunofluorescent analysis using the Antibody at 1:150 dilution.



Immunofluorescent analysis using the Antibody at 1:500 dilution.



Western blot analysis of COX2 expression in RAW264.7 cell lysate treated with LPS.



Immunofluorescent analysis of Hela cells, using COX2 Antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.